GSK PLC has a consensus price target of $48 based on the ratings of 7 analysts. The high is $53 issued by Jefferies on July 2, 2024. The low is $44 issued by Morgan Stanley on January 23, 2024. The 3 most-recent analyst ratings were released by Jefferies, Goldman Sachs, and Morgan Stanley on July 2, 2024, May 30, 2024, and January 23, 2024, respectively. With an average price target of $48 between Jefferies, Goldman Sachs, and Morgan Stanley, there's an implied 16.99% upside for GSK PLC from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for GSK (NYSE:GSK) was reported by UBS on July 8, 2024. The analyst firm set a price target for $0.00 expecting GSK to fall to within 12 months (a possible -100.00% downside). 6 analyst firms have reported ratings in the last year.
The latest analyst rating for GSK (NYSE:GSK) was provided by UBS, and GSK downgraded their neutral rating.
The last upgrade for GSK PLC happened on March 4, 2024 when Guggenheim raised their price target to N/A. Guggenheim previously had a neutral for GSK PLC.
The last downgrade for GSK PLC happened on July 8, 2024 when UBS changed their price target from N/A to N/A for GSK PLC.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of GSK, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for GSK was filed on July 8, 2024 so you should expect the next rating to be made available sometime around July 8, 2025.
While ratings are subjective and will change, the latest GSK (GSK) rating was a downgraded with a price target of $0.00 to $0.00. The current price GSK (GSK) is trading at is $41.03, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.